The S&P 500 Index (SPX) generated “unusually strong” return during the first three quarters of 2024 – compared to the ...

Investment firm Barclays laid out its thoughts for the technology space in 2025 in a research note on Thursday. Read for more ...

Amazon’s satellite broadband initiative, Project Kuiper, shows huge potential. Find out why AMZN stock could thrive with a ...

Barclays Plc’s Stephen Dainton is preparing for a wave of dealmaking this year as more US companies have been buoyed by ...

Emmanuel Cau, head of European equity strategy at Barclays, weighs in on the outlook for European stocks in 2025.

Barclays PLC BARC shares slid 2.60% to £2.66 Tuesday, on what proved to be an all-around grim trading session for the stock ...

From China to Europe, Canada to Mexico, world markets are already reeling from Donald Trump's promise to jack up tariffs when ...

China, the global growth engine for the last 20 years, now boasts lower long-term bond yields than Japan, the former poster ...

Simple volatility is the biggest risk for retail investors. Crypto coins, tokens, and currencies are “purely speculative,” ...

Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.

In a report released today, Seth Sigman from Barclays maintained a Hold rating on Five Below (FIVE – Research Report), with a price target of ...

On Wednesday, Barclays PLC (BCS) stock saw a decline, ending the day at $13.19 which represents a decrease of $-0.06 or -0.45% from the prior close of $13.25. The stock opened at $13.01 and touched a ...